Advanced search
1 file | 281.22 KB

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Monirath Hav (UGent) , Louis Libbrecht (UGent) , Liesbeth Ferdinande (UGent) , Piet Pattyn (UGent) , Stéphanie Laurent (UGent) , Marc Peeters (UGent) , Marleen Praet (UGent) and Patrick Pauwels (UGent)
(2011) VIRCHOWS ARCHIV. 458(2). p.197-203
Author
Organization
Abstract
The aim of this study was to investigate murine double minute-2 (MDM2) gene copy number changes in colon carcinoma and to correlate these findings with an immunohistochemical analysis of MDM2 protein expression and histopathologic prognostic indicators of the tumors. The study included 80 cases of sporadic colon carcinomas. MDM2 protein expression was assessed by immunohistochemistry, and MDM2 gene status by fluorescence in situ hybridization. MDM2 gene amplification was detected in 18% of the 80 cases examined. A strong correlation was found between MDM2 gene amplification and the presence, intensity, and staining proportion of cytoplasmic MDM2 protein expression (p = 0.01). No correlation was found between MDM2 gene amplification and the well-established histopathologic prognostic factors. Given the correlation with gene amplification, we clearly demonstrated that cytoplasmic expression of MDM2 protein is true and relevant and that this finding has to be taken into account when immunohistochemistry would be used as a screening for MDM2 gene amplification in the near future. Targeting MDM2 could be a new approach in colon cancer therapy. The amplification status could be a predictive factor of the response to MDM2-targeted therapy.
Keywords
SUPPRESSOR, MESSENGER-RNA, INHIBITORS, ACTIVATION, SNP309, IN-VIVO, ONCOPROTEIN MDM2, P53 FUNCTION, CANCER-THERAPY, ACCELERATES TUMOR-FORMATION, Targeted treatment in colon carcinoma, Colon carcinoma, MDM2 in colon carcinoma, MDM2 gene amplification, MDM2, MDM2 protein expression

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 281.22 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Hav, Monirath, Louis Libbrecht, Liesbeth Ferdinande, Piet Pattyn, Stéphanie Laurent, Marc Peeters, Marleen Praet, and Patrick Pauwels. 2011. “MDM2 Gene Amplification and Protein Expressions in Colon Carcinoma: Is Targeting MDM2 a New Therapeutic Option?” Virchows Archiv 458 (2): 197–203.
APA
Hav, M., Libbrecht, L., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M., et al. (2011). MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? VIRCHOWS ARCHIV, 458(2), 197–203.
Vancouver
1.
Hav M, Libbrecht L, Ferdinande L, Pattyn P, Laurent S, Peeters M, et al. MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? VIRCHOWS ARCHIV. 2011;458(2):197–203.
MLA
Hav, Monirath, Louis Libbrecht, Liesbeth Ferdinande, et al. “MDM2 Gene Amplification and Protein Expressions in Colon Carcinoma: Is Targeting MDM2 a New Therapeutic Option?” VIRCHOWS ARCHIV 458.2 (2011): 197–203. Print.
@article{2017026,
  abstract     = {The aim of this study was to investigate murine double minute-2 (MDM2) gene copy number changes in colon carcinoma and to correlate these findings with an immunohistochemical analysis of MDM2 protein expression and histopathologic prognostic indicators of the tumors. The study included 80 cases of sporadic colon carcinomas. MDM2 protein expression was assessed by immunohistochemistry, and MDM2 gene status by fluorescence in situ hybridization. MDM2 gene amplification was detected in 18% of the 80 cases examined. A strong correlation was found between MDM2 gene amplification and the presence, intensity, and staining proportion of cytoplasmic MDM2 protein expression (p = 0.01). No correlation was found between MDM2 gene amplification and the well-established histopathologic prognostic factors. Given the correlation with gene amplification, we clearly demonstrated that cytoplasmic expression of MDM2 protein is true and relevant and that this finding has to be taken into account when immunohistochemistry would be used as a screening for MDM2 gene amplification in the near future. Targeting MDM2 could be a new approach in colon cancer therapy. The amplification status could be a predictive factor of the response to MDM2-targeted therapy.},
  author       = {Hav, Monirath and Libbrecht, Louis and Ferdinande, Liesbeth and Pattyn, Piet and Laurent, Stéphanie and Peeters, Marc and Praet, Marleen and Pauwels, Patrick},
  issn         = {0945-6317},
  journal      = {VIRCHOWS ARCHIV},
  keywords     = {SUPPRESSOR,MESSENGER-RNA,INHIBITORS,ACTIVATION,SNP309,IN-VIVO,ONCOPROTEIN MDM2,P53 FUNCTION,CANCER-THERAPY,ACCELERATES TUMOR-FORMATION,Targeted treatment in colon carcinoma,Colon carcinoma,MDM2 in colon carcinoma,MDM2 gene amplification,MDM2,MDM2 protein expression},
  language     = {eng},
  number       = {2},
  pages        = {197--203},
  title        = {MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?},
  url          = {http://dx.doi.org/10.1007/s00428-010-1012-7},
  volume       = {458},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: